Chen S, et al. - Researchers compared the overall survival (OS) in cirrhotic patients with resectable intermediate-stage HCC (HCC) resulting from liver resection (LR) vs transarterial chemoembolization (TACE). They developed a Markov model, comparing LR with TACE over 15 years, based on the data from 31 literatures and was externally validated of the model using a data set (n = 1,735; LR: 701; TACE: 1,034) from a tertiary center. Based on the Markov model, researchers suggest a possible benefit of LR in terms of better OS for these patients, compared to TACE. The 5-year survival rates in the validation set following LR were significantly improved vs those following TACE before (40.2% vs. 25.9%) and after matching (43.2% vs 30.9%), similar to the model results.